|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
NLM112615724 |
003 |
DE-627 |
005 |
20250202154351.0 |
007 |
tu |
008 |
231222s2001 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed25n0376.xml
|
035 |
|
|
|a (DE-627)NLM112615724
|
035 |
|
|
|a (NLM)11355361
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Puthalakath, H
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Rapid selection against truncation mutants in yeast reverse two-hybrid screens
|
264 |
|
1 |
|c 2001
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 04.12.2001
|
500 |
|
|
|a Date Revised 28.09.2018
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a ErratumIn: Biotechniques 2001 Sep;31(3):488
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a The yeast reverse two-hybrid system is a powerful technique for isolating mutations in a protein that abolish its interaction with a known partner. Selection is based on abrogation of growth suppression imposed when wild-type interactions confer 5-fluoroorotic acid (5-FOA) sensitivity to yeast cells. A laborious component of this system is to eliminate those mutations that cause protein truncation. By fusing the green fluorescent protein (GFP) to the C-terminus of a protein of interest, dynein light chain (LC8), we were able to rapidly isolate mutations that did not result in protein truncation
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
650 |
|
4 |
|a Technical Report
|
650 |
|
4 |
|a Journal Article
|
650 |
|
7 |
|a Apoptosis Regulatory Proteins
|2 NLM
|
650 |
|
7 |
|a Bcl-2-Like Protein 11
|2 NLM
|
650 |
|
7 |
|a Carrier Proteins
|2 NLM
|
650 |
|
7 |
|a Drosophila Proteins
|2 NLM
|
650 |
|
7 |
|a Luminescent Proteins
|2 NLM
|
650 |
|
7 |
|a Membrane Proteins
|2 NLM
|
650 |
|
7 |
|a Proto-Oncogene Proteins
|2 NLM
|
650 |
|
7 |
|a Recombinant Fusion Proteins
|2 NLM
|
650 |
|
7 |
|a Green Fluorescent Proteins
|2 NLM
|
650 |
|
7 |
|a 147336-22-9
|2 NLM
|
650 |
|
7 |
|a Orotic Acid
|2 NLM
|
650 |
|
7 |
|a 61H4T033E5
|2 NLM
|
650 |
|
7 |
|a 5-fluoroorotic acid
|2 NLM
|
650 |
|
7 |
|a 7IA9OUC93E
|2 NLM
|
650 |
|
7 |
|a beta-Galactosidase
|2 NLM
|
650 |
|
7 |
|a EC 3.2.1.23
|2 NLM
|
650 |
|
7 |
|a Dyneins
|2 NLM
|
650 |
|
7 |
|a EC 3.6.4.2
|2 NLM
|
650 |
|
7 |
|a Fluorouracil
|2 NLM
|
650 |
|
7 |
|a U3P01618RT
|2 NLM
|
700 |
1 |
|
|a Strasser, A
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Huang, D C
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t BioTechniques
|d 1993
|g 30(2001), 5 vom: 01. Mai, Seite 984-8
|w (DE-627)NLM012627046
|x 0736-6205
|7 nnns
|
773 |
1 |
8 |
|g volume:30
|g year:2001
|g number:5
|g day:01
|g month:05
|g pages:984-8
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_21
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_39
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_50
|
912 |
|
|
|a GBV_ILN_60
|
912 |
|
|
|a GBV_ILN_62
|
912 |
|
|
|a GBV_ILN_65
|
912 |
|
|
|a GBV_ILN_70
|
912 |
|
|
|a GBV_ILN_99
|
912 |
|
|
|a GBV_ILN_121
|
912 |
|
|
|a GBV_ILN_130
|
912 |
|
|
|a GBV_ILN_227
|
912 |
|
|
|a GBV_ILN_350
|
912 |
|
|
|a GBV_ILN_618
|
912 |
|
|
|a GBV_ILN_640
|
912 |
|
|
|a GBV_ILN_754
|
912 |
|
|
|a GBV_ILN_2001
|
912 |
|
|
|a GBV_ILN_2002
|
912 |
|
|
|a GBV_ILN_2003
|
912 |
|
|
|a GBV_ILN_2005
|
912 |
|
|
|a GBV_ILN_2006
|
912 |
|
|
|a GBV_ILN_2007
|
912 |
|
|
|a GBV_ILN_2008
|
912 |
|
|
|a GBV_ILN_2009
|
912 |
|
|
|a GBV_ILN_2010
|
912 |
|
|
|a GBV_ILN_2012
|
912 |
|
|
|a GBV_ILN_2015
|
912 |
|
|
|a GBV_ILN_2018
|
912 |
|
|
|a GBV_ILN_2023
|
912 |
|
|
|a GBV_ILN_2035
|
912 |
|
|
|a GBV_ILN_2040
|
912 |
|
|
|a GBV_ILN_2060
|
912 |
|
|
|a GBV_ILN_2099
|
912 |
|
|
|a GBV_ILN_2105
|
912 |
|
|
|a GBV_ILN_2121
|
912 |
|
|
|a GBV_ILN_2470
|
951 |
|
|
|a AR
|
952 |
|
|
|d 30
|j 2001
|e 5
|b 01
|c 05
|h 984-8
|